Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could clear psoriasis in thousands

NCT ID NCT07432854

Disease control Sponsor: Dermavon Holdings Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental tablet called CMS-D001 for adults with moderate to severe plaque psoriasis. About 540 participants will receive either the drug or a placebo to see if it improves skin symptoms like redness, scaling, and thickness. The goal is to measure how many people achieve at least 75% clearer skin after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 540 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18-75 years, willing to sign the ICF * Diagnosed with plaque psoriasis for at least 6 months prior to screening. * At screening and baseline, PASI score ≥ 12 points, BSA ≥ 10%, sPGA ≥ 3 * Be eligible for phototherapy or systemic therapy. Exclusion Criteria: * Non-plaque psoriasis (ie, guttate, pustular, erythrodermic, or inverse psoriasis) within 3 months prior to baseline. * Other skin diseases at screening or baseline Drug-induced psoriasis. * History of severe herpes zoster or severe herpes simplex or current herpes simplex/zoster infection. * History of a serious bacterial, fungal, or viral infection requiring hospitalization or intravenous antimicrobial therapy within 3 months prior to the first dose. * History of a bacterial, fungal, or viral infection requiring oral antimicrobial therapy within 4 weeks prior to the first dose. * Active infection or acute illness within 7 days prior to the first dose. Chronic or recurrent infectious diseases at screening or baseline that, in the investigator's judgment, may increase safety risks. * Evidence of active TB. Patients with evidence of latent tuberculosis may enter the trial after sufficient treatment had initiated and maintained according to protocol. * History of a major or unstable clinical condition within 6 months prior to the first dose, which would compromise participation. * History of malignant tumour within 5 years before screening. * Previous or current autoimmune diseases. * Positive results of confirmatory test for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or syphilis. * Allergic to any component of the investigational drug.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate to severe plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate to severe plaque psoriasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    21 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Chengde Medical College

    Chengde, Hebei, China

  • Affiliated Hospital of Hebei University of Engineering

    Handan, Hebei, China

  • Beijing Tongren Hospital Affiliated to Capital Medical University

    Beijing, China

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • Jining First People's Hospital

    Jining, Shandong, China

  • Nanyang Central Hospital

    Nanyang, Henan, China

  • Sanmenxia Central Hospital

    Sanmenxia, Henan, China

  • Shandong First Medical University Affiliated Dermatology Hospital

    Jinan, Shangdong, China

  • Shanghai Dermatology Hospital

    Shanghai, China

  • Shijiazhuang Traditional Chinese Medicine Hospital

    Shijiazhuang, Hebei, China

  • Southern Medical University Dermatology Hospital

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Wannan Medical College (Yijishan)

    Wuhu, Anhui, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The Fourth Affiliated Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Wuxi Second People's Hospital

    Wuxi, Jiangsu, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.